These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7879251)

  • 1. Successful appetite suppression therapy with fenfluramine and phentermine in the obese diabetic transplant patient.
    Khan M; Lum CT; Rao V
    Transplant Proc; 1995 Feb; 27(1):975-6. PubMed ID: 7879251
    [No Abstract]   [Full Text] [Related]  

  • 2. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity.
    Rothman RB
    J Clin Psychiatry; 1996 Feb; 57(2):92-3. PubMed ID: 8591979
    [No Abstract]   [Full Text] [Related]  

  • 5. A trial of fenfluramine (PACaps) and diet in overweight diabetic patients.
    Wells HM
    Postgrad Med J; 1975; 51 Suppl 1(593):137. PubMed ID: 1219672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
    Daniele E; Coco MP
    Clin Ter; 1996 Apr; 147(4):199-204. PubMed ID: 8766352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease.
    Pontiroli AE; Calderara A; Pacchioni M; Cassisa C; Pozza G
    Diabete Metab; 1993; 19(1):30-5. PubMed ID: 8504882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative unresponsiveness of obese diabetic compared to obese non-diabetic subjects to the weight-reducing effect of fenfluramine.
    Otim MA
    East Afr Med J; 1977 Feb; 54(2):91-5. PubMed ID: 885093
    [No Abstract]   [Full Text] [Related]  

  • 13. The relationship between health-related quality of life and weight loss.
    Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S
    Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of phentermine in obese diabetic patients.
    Campbell CJ; Bhalla IP; Steel JM; Duncan LJ
    Practitioner; 1977 Jun; 218(1308):851-5. PubMed ID: 329259
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term drug treatment of obesity in a private practice setting.
    Atkinson RL; Blank RC; Schumacher D; Dhurandhar NV; Ritch DL
    Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is it possible to obtain a reduction of body weight exclusively via a loss in fat mass? Experience with d-fenfluramine].
    Del Ponte A; D'Orazio N; Di Giacomo G; Tritella T; Bitti G; Martines G
    Recenti Prog Med; 1993 Feb; 84(2):100-5. PubMed ID: 8465086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of new formulation of fenfluramine in the management of the obese, diabetic African.
    Wilton D
    Postgrad Med J; 1975; 51 Suppl 1():138-9. PubMed ID: 1219673
    [No Abstract]   [Full Text] [Related]  

  • 18. Appetite suppressants for obesity.
    Budenholzer B
    J Fam Pract; 1997 Jan; 44(1):19-20. PubMed ID: 9010359
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
    Weintraub M; Sundaresan PR; Schuster B; Moscucci M; Stein EC
    Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss.
    Katz DA; Maloney MJ; Sutkamp JC; McConville BJ
    Int J Eat Disord; 1999 May; 25(4):469-74. PubMed ID: 10202659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.